Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04497389 · ClinicalTrials.gov registry record · Phase 1
Safety and Feasibility of Amniotic Fluid as a Treatment for COVID-19 Patients
A Phase 1 study, sponsored by University of Utah.
- Completed
- Registry status
- Phase 1
- Development phase
- 47
- Enrollment target
NCT04497389: Completed Phase 1 study, sponsored by University of Utah.
NCT04497389 is a Phase 1 study that has completed, run by University of Utah. The registered enrollment target is 47 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (22% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04497389, a Phase 1 study, has completed, sponsored by University of Utah.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 47 participants
- Enrollment target
Study Summary
The purpose of this study is to explore the effectiveness of processed human amniotic fluid as a treatment for COVID-19.
Primary Outcome
Assess reduction of inflammation in COVID-19 patients, potentially leading to a decrease in the need for critical care. This will be assessed by measurement of C-reactive protein levels before and after the intervention. Units: mg/dL
Interventions
- BIOLOGICAL Human Amniotic Fluid
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 47 participants |
| Start Date | 2020-10-28 |
| Est. Completion | 2023-02-15 |
| Phase | Phase 1 |
What the finished NCT04497389 record still lists
NCT04497389 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 47 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (22% lower).
The record links to 0 conditions, and to 1 intervention - of which Human Amniotic Fluid is the first listed.
NCT04497389 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04497389 about?
NCT04497389 is a clinical study titled "Safety and Feasibility of Amniotic Fluid as a Treatment for COVID-19 Patients". The purpose of this study is to explore the effectiveness of processed human amniotic fluid as a treatment for COVID-19.
What is the current status of trial NCT04497389?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 47 participants. The study started on 2020-10-28. Estimated completion is 2023-02-15.
What interventions are being tested in trial NCT04497389?
The interventions under investigation include: Human Amniotic Fluid (BIOLOGICAL).
Who is sponsoring clinical trial NCT04497389?
This trial is sponsored by University of Utah, which has 818 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04497389's enrollment target sits among peer trials
47 1053rd of 2000 higher than 943 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03313011 · 47 participants
The Neurobiology of Two Distinct Types of Progressive Apraxia of Speech
- NCT03467516 · 47 participants · Phase 2
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Metastatic Uveal Melanoma
- NCT03886662 · 47 participants · Phase 1
A Study of LB-100 in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS)
- NCT04013802 · 47 participants · Phase 1
TETRAVI Multivirus CTL for Treatment of EBV, CMV, Adenovirus, and BK Infections Post Allogeneic SCT.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI